204 related articles for article (PubMed ID: 31654094)
1. Potent repression of C-reactive protein (CRP) expression by the JAK1/2 inhibitor ruxolitinib in inflammatory human hepatocytes.
Febvre-James M; Lecureur V; Fardel O
Inflamm Res; 2020 Jan; 69(1):51-62. PubMed ID: 31654094
[TBL] [Abstract][Full Text] [Related]
2. The JAK1/2 Inhibitor Ruxolitinib Reverses Interleukin-6-Mediated Suppression of Drug-Detoxifying Proteins in Cultured Human Hepatocytes.
Febvre-James M; Bruyère A; Le Vée M; Fardel O
Drug Metab Dispos; 2018 Feb; 46(2):131-140. PubMed ID: 29162613
[TBL] [Abstract][Full Text] [Related]
3. Repression of interferon β-regulated cytokines by the JAK1/2 inhibitor ruxolitinib in inflammatory human macrophages.
Febvre-James M; Lecureur V; Augagneur Y; Mayati A; Fardel O
Int Immunopharmacol; 2018 Jan; 54():354-365. PubMed ID: 29202299
[TBL] [Abstract][Full Text] [Related]
4. Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: Perspectives for scleroderma-associated interstitial lung disease.
Lescoat A; Lelong M; Jeljeli M; Piquet-Pellorce C; Morzadec C; Ballerie A; Jouneau S; Jego P; Vernhet L; Batteux F; Fardel O; Lecureur V
Biochem Pharmacol; 2020 Aug; 178():114103. PubMed ID: 32562787
[TBL] [Abstract][Full Text] [Related]
5. The JAK1/JAK2- inhibitor ruxolitinib inhibits mast cell degranulation and cytokine release.
Hermans MAW; Schrijver B; van Holten-Neelen CCPA; Gerth van Wijk R; van Hagen PM; van Daele PLA; Dik WA
Clin Exp Allergy; 2018 Nov; 48(11):1412-1420. PubMed ID: 29939445
[TBL] [Abstract][Full Text] [Related]
6. JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms.
Parampalli Yajnanarayana S; Stübig T; Cornez I; Alchalby H; Schönberg K; Rudolph J; Triviai I; Wolschke C; Heine A; Brossart P; Kröger N; Wolf D
Br J Haematol; 2015 Jun; 169(6):824-33. PubMed ID: 25824483
[TBL] [Abstract][Full Text] [Related]
7. Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia.
Maude SL; Tasian SK; Vincent T; Hall JW; Sheen C; Roberts KG; Seif AE; Barrett DM; Chen IM; Collins JR; Mullighan CG; Hunger SP; Harvey RC; Willman CL; Fridman JS; Loh ML; Grupp SA; Teachey DT
Blood; 2012 Oct; 120(17):3510-8. PubMed ID: 22955920
[TBL] [Abstract][Full Text] [Related]
8. The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19.
Goker Bagca B; Biray Avci C
Cytokine Growth Factor Rev; 2020 Aug; 54():51-62. PubMed ID: 32636055
[TBL] [Abstract][Full Text] [Related]
9. LPS-induced inflammation desensitizes hepatocytes to Fas-induced apoptosis through Stat3 activation-The effect can be reversed by ruxolitinib.
Markotic A; Flegar D; Grcevic D; Sucur A; Lalic H; Turcic P; Kovacic N; Lukac N; Pravdic D; Vukojevic K; Cavar I; Kelava T
J Cell Mol Med; 2020 Mar; 24(5):2981-2992. PubMed ID: 32022429
[TBL] [Abstract][Full Text] [Related]
10. New Concepts of Treatment for Patients with Myelofibrosis.
Bose P; Alfayez M; Verstovsek S
Curr Treat Options Oncol; 2019 Jan; 20(1):5. PubMed ID: 30675650
[TBL] [Abstract][Full Text] [Related]
11. Atomic Simulation of the Binding of JAK1 and JAK2 with the Selective Inhibitor Ruxolitinib.
Kondratyev M; Rudnev VR; Nikolsky KS; Stepanov AA; Petrovsky DV; Kulikova LI; Kopylov AT; Malsagova KA; Kaysheva AL
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142375
[TBL] [Abstract][Full Text] [Related]
12. Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer.
Fogelman D; Cubillo A; García-Alfonso P; Mirón MLL; Nemunaitis J; Flora D; Borg C; Mineur L; Vieitez JM; Cohn A; Saylors G; Assad A; Switzky J; Zhou L; Bendell J
Cancer Med; 2018 Nov; 7(11):5382-5393. PubMed ID: 30123970
[TBL] [Abstract][Full Text] [Related]
13. [The anti-proliferative and anti-inflammatory mechanisms of JAK1 inhibitor SHR0302 versus Ruxolitinib in SET2 cell line and primary cells].
Yang AY; Liu JQ; Cai YN; Fang MY; Yang L; Chen M; Li B; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2019 Dec; 40(12):1003-1007. PubMed ID: 32023730
[No Abstract] [Full Text] [Related]
14. Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patients.
de Oliveira MB; Fook-Alves VL; Eugenio AIP; Fernando RC; Sanson LFG; de Carvalho MF; Braga WMT; Davies FE; Colleoni GWB
Cancer Lett; 2017 Sep; 403():206-215. PubMed ID: 28645562
[TBL] [Abstract][Full Text] [Related]
15. Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata.
Dai Z; Chen J; Chang Y; Christiano AM
JCI Insight; 2021 Apr; 6(7):. PubMed ID: 33830087
[TBL] [Abstract][Full Text] [Related]
16. Effects of JAK1/2 inhibition on bone marrow stromal cells of myeloproliferative neoplasm (MPN) patients and healthy individuals.
Zacharaki D; Ghazanfari R; Li H; Lim HC; Scheding S
Eur J Haematol; 2018 Jul; 101(1):57-67. PubMed ID: 29645296
[TBL] [Abstract][Full Text] [Related]
17. Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis.
Vaddi K; Sarlis NJ; Gupta V
Expert Opin Pharmacother; 2012 Nov; 13(16):2397-407. PubMed ID: 23051187
[TBL] [Abstract][Full Text] [Related]
18. Tumoricidal effects of the JAK inhibitor Ruxolitinib (INC424) on hepatocellular carcinoma in vitro.
Wilson GS; Tian A; Hebbard L; Duan W; George J; Li X; Qiao L
Cancer Lett; 2013 Dec; 341(2):224-30. PubMed ID: 23941832
[TBL] [Abstract][Full Text] [Related]
19. IL-6 stimulation of DNA replication is JAK1/2 mediated in cross-talk with hyperactivated ERK1/2 signaling.
Subotički T; Mitrović Ajtić O; Beleslin-Čokić BB; Bjelica S; Djikić D; Diklić M; Leković D; Gotić M; Santibanez JF; Noguchi CT; Čokić VP
Cell Biol Int; 2019 Feb; 43(2):192-206. PubMed ID: 30571852
[TBL] [Abstract][Full Text] [Related]
20. Janus kinase-dependent regulation of drug detoxifying protein expression by interleukin-22 in human hepatic cells.
Le Vée M; Bruyère A; Jouan E; Fardel O
Int Immunopharmacol; 2020 Jun; 83():106439. PubMed ID: 32234672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]